NCT04892134

Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis

Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis - MarkMS

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Medical University of Graz · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

By combining clinical, morphological and biochemical markers a better understanding of the formation and progression of multiple sclerosis (MS) should be obtained

Detailed description

The current study aims to comprehensively investigate the individual clinical, morphological and biochemical aspects of MS in order to elucidate underlying mechanisms leading to disease progression. This shall ultimately serve to identify imaging and biochemical markers, which may support clinical management of persons with MS (pwMS). The following markers will be assessed: demographics (age, sex), clinical (EDSS at baseline, disease duration); neuropsychological (SDMT (Symbol Digit Modalities Test) score); MRI (Magnetic Resonance Imaging) (lesion load, atrophy); Biochemical markers analyzed in cerebrospinal fluid (CSF), blood, DNA, RNA, peripheral blood mononuclear cells (PBMCs)

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
OTHER	blood sample	40-50 ml of blood is taken

Timeline

• Start date: 2019-10-03
• Primary completion: 2024-10-31
• Completion: 2025-10-31
• First posted: 2021-05-19
• Last updated: 2023-10-19

Locations

1 site across 1 country: Austria